The stock of Voyager Therapeutics Inc. (NASDAQ:VYGR) last traded at $11.49, up 0.35% from the previous session.
As we calculate the median target price by taking the range between a high of $18.00 and a low of $9.00, we find $14.50. Given the previous closing price of $11.45, this indicates a potential upside of 26.64 percent. VYGR stock price is now 5.17% away from the 50-day moving average and 46.16% away from the 200-day moving average. The market capitalization of the company currently stands at $516.48M.
Brokers who have rated the stock have averaged $13.67 as their price target over the next twelve months.
With the price target of $18, Truist recently initiated with Buy rating for Voyager Therapeutics Inc. (NASDAQ: VYGR).
In other news, Sandrock Alfred, President and CEO sold 7,437 shares of the company’s stock on Apr 03. The stock was sold for $58,232 at an average price of $7.83. Upon completion of the transaction, the President and CEO now directly owns 214,618 shares in the company, valued at $2.47 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Apr 03, Chief Operating Officer Swartz Robin sold 1,259 shares of the business’s stock. A total of $9,858 was realized by selling the stock at an average price of $7.83. This leaves the insider owning 71,617 shares of the company worth $0.82 million. Insiders disposed of 4,179,584 shares of company stock worth roughly $48.02 million over the past 1 year. A total of 0.60% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in VYGR stock. A new stake in Voyager Therapeutics Inc. shares was purchased by FARALLON CAPITAL MANAGEMENT LLC during the first quarter worth $8,966,000. ASSENAGON ASSET MANAGEMENT S.A. invested $1,273,000 in shares of VYGR during the first quarter. In the first quarter, CUBIST SYSTEMATIC STRATEGIES, LLC acquired a new stake in Voyager Therapeutics Inc. valued at approximately $1,076,000. HRT FINANCIAL LP acquired a new stake in VYGR for approximately $1,022,000. MARSHALL WACE, LLP purchased a new stake in VYGR valued at around $754,000 in the second quarter. In total, there are 97 active investors with 61.20% ownership of the company’s stock.
With an opening price of $11.50 on Monday morning, Voyager Therapeutics Inc. (NASDAQ: VYGR) set off the trading day. During the past 12 months, Voyager Therapeutics Inc. has had a low of $4.77 and a high of $14.34. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 15.20, and a quick ratio of 15.20. The fifty day moving average price for VYGR is $10.92 and a two-hundred day moving average price translates $7.86 for the stock.
The latest earnings results from Voyager Therapeutics Inc. (NASDAQ: VYGR) was released for Mar, 2023. According to the Biotechnology Company, earnings per share came in at $2.94, beating analysts’ expectations of $0.77 by 2.17. This compares to -$0.56 EPS in the same period last year. The company reported revenue of $150.48 million for the quarter, compared to $0.66 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 22769.3 percent. For the current quarter, analysts expect VYGR to generate $1.6M in revenue.
Voyager Therapeutics Inc.(VYGR) Company Profile
Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company’s lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of Alzheimer’s disease. It also develops VY-FXN01 to treat Friedreich’s ataxia; superoxide dismutase 1 gene silencing program for the treatment of amyotrophic lateral sclerosis; and GBA1 gene replacement program to treat Parkinson’s disease. In addition, the company develops research program for the treatment of Huntington’s disease. It has collaboration and license agreements with Neurocrine Biosciences, Inc.; Pfizer Inc.; and Novartis Pharma, A.G. for the research, development, and commercialization of adeno-associated virus gene therapy products. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.
